Neumora Therapeutics, Inc. (NMRA) total assets
Neumora Therapeutics, Inc. (NMRA) had total assets of $191.05M at the end of fiscal 2025 (December 31, 2025). That is 39.7% lower than the $316.97M of fiscal 2024. Figures as of 18 Nov 2026, 12:35 UTC, from Yahoo Finance.
Key facts
- Total assets, fiscal 2025
- $191.05M
- Change on fiscal 2024
- −39.7%
- Highest on record
- $496.20Mfiscal 2023
- Lowest on record
- $191.05Mfiscal 2025
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Neumora Therapeutics, Inc. total assets, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $496.20M in fiscal 2023 and the lowest $191.05M in fiscal 2025.
Total assets by fiscal year
Neumora Therapeutics, Inc. total assets, year by year
| Fiscal year | Total assets | Change | Year ended |
|---|---|---|---|
| 2025 | $191.05M | 39.7% down | |
| 2024 | $316.97M | 36.1% down | |
| 2023 | $496.20M | 16.4% up | |
| 2022 | $426.23M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
How to read it
It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.
Neumora Therapeutics, Inc., figure by figure
- Neumora Therapeutics, Inc. market cap
- Neumora Therapeutics, Inc. revenue
- Neumora Therapeutics, Inc. earnings
- Neumora Therapeutics, Inc. earnings per share (EPS)
- Neumora Therapeutics, Inc. P/E ratio
- Neumora Therapeutics, Inc. P/S ratio
- Neumora Therapeutics, Inc. P/B ratio
- Neumora Therapeutics, Inc. free cash flow
- Neumora Therapeutics, Inc. operating margin
- Neumora Therapeutics, Inc. dividend
- Neumora Therapeutics, Inc. shares outstanding
- Neumora Therapeutics, Inc. total debt
- Neumora Therapeutics, Inc. cash on hand
- Neumora Therapeutics, Inc. return on equity (ROE)
- Neumora Therapeutics, Inc. return on invested capital (ROIC)
Neumora Therapeutics, Inc. (NMRA) overview: price, valuation and scorecard
Neumora Therapeutics, Inc. total assets: questions and answers
How large are Neumora Therapeutics, Inc.'s total assets?
Neumora Therapeutics, Inc. (NMRA) had total assets of $191.05M at the end of fiscal 2025 (December 31, 2025). That is 39.7% lower than the $316.97M of fiscal 2024.
What are the highest and lowest total assets figures on record for Neumora Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $496.20M in fiscal 2023 and the lowest $191.05M in fiscal 2025.
How is Neumora Therapeutics, Inc.'s total assets calculated?
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest. For Neumora Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: total assets
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Neumora Therapeutics, Inc. (NMRA) total assets”, data as of 18 November 2026. https://funkfolio.com/stock/NMRA/total-assets
Underlying data: Yahoo Finance.